WDFC:NASDAQWD-40 Company Analysis
Data as of 2026-07-29 - not real-time
$222.40
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
WD‑40 posted a 24.3% year‑over‑year revenue increase to $195.1 million in Q2 2026, underscoring the strength of its product portfolio. The company’s full‑year revenue guidance of $682.5 million sits ~3.4% above analyst consensus, indicating confidence in continued top‑line momentum. GAAP earnings of $2.24 per share beat expectations by 43%, reflecting robust operating margins (≈21%) and a healthy profit margin of 13.2%. With a ROE of 33% and operating cash flow of $84.8 million, the business generates ample cash to fund growth and dividends. However, the current market price of $222.4 is roughly 30% above the DCF‑derived fair value of $172, and valuation multiples (PE ≈ 34×, PB ≈ 10.7×) suggest the stock is overvalued. The dividend yield of 1.75% is supported by a payout ratio of ~60%, indicating sustainability.
Technically, the share price sits just above the identified support at $219 but remains below the 20‑day SMA of $242, hinting at short‑term downside pressure. The RSI of 38 points to mild oversold conditions, while the MACD histogram is negative and the signal line is bearish, suggesting momentum could turn lower. Volatility over the past 30 days is elevated at ~47%, yet the beta of 0.08 signals very low systematic risk relative to the market. Investor sentiment is in “Extreme Greed” territory (Fear & Greed Index 84.5), which may be inflating price expectations. Given the strong fundamentals but lofty valuation, a cautious stance is warranted until price alignment occurs. Overall, the stock offers a solid dividend and resilient cash flow, but short‑term traders should monitor technical weakness while long‑term investors may view the current level as a premium entry point.
Technically, the share price sits just above the identified support at $219 but remains below the 20‑day SMA of $242, hinting at short‑term downside pressure. The RSI of 38 points to mild oversold conditions, while the MACD histogram is negative and the signal line is bearish, suggesting momentum could turn lower. Volatility over the past 30 days is elevated at ~47%, yet the beta of 0.08 signals very low systematic risk relative to the market. Investor sentiment is in “Extreme Greed” territory (Fear & Greed Index 84.5), which may be inflating price expectations. Given the strong fundamentals but lofty valuation, a cautious stance is warranted until price alignment occurs. Overall, the stock offers a solid dividend and resilient cash flow, but short‑term traders should monitor technical weakness while long‑term investors may view the current level as a premium entry point.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near support level
- RSI indicating oversold conditions
- bearish MACD momentum
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- strong revenue and earnings growth
- high ROE and cash flow generation
- valuation premium relative to DCF
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- sustainable dividend payout
- global brand moat
- consistent free cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth24.30%
Profit Margin13.23%
P/E Ratio34.4
ROE33.31%
ROA15.42%
Debt/Equity41.05
P/B Ratio10.7
Op. Cash Flow$84.8M
Free Cash Flow$68.6M
Technical Analysis
TrendBullish
RSI38.8
Support$219.00
Resistance$298.90
MA 20$242.55
MA 50$227.36
MA 200$215.04
MACDBearish
VolumeDecreasing
Fear & Greed Index84.54
Valuation
Fair Value$171.99
Target Price$271.67
Upside/Downside22.15%
GradeOvervalued
TypeGrowth
Dividend Yield1.75%
Risk Assessment
Beta0.08
Volatility47.39%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.